A number of clinical studies have shown that treatment of NSCLC cells with EGFR TKIs can induce increased EGFR/IGF-1R heterodimerization and IGF-1R activation [9, 34], enhancing the downstream PI3K/Akt and Mek/Erk pathways [9]. Here, IGF1R is linked to non-small cell lung carcinoma.